Biology and Experience of Eating

Obesity is associated with greater risk for cardiovascular disease (CVD), stroke, diabetes,
and mortality, and is a heterogeneous condition with various causes and thus a diversity of
intervention targets. Compulsive overeating afflicts 30% of people seeking obesity treatment
and increases risk for CVD factors. This trial involves two participant visits to test
whether opioid blockade (Day 1 or 2, depending on randomization), compared to placebo (Day 1
or 2, depending on randomization), will elicit common symptoms of opioid withdrawal,
including nausea. Participants will receive each condition on separate days.

Inclusion Criteria:

- Obese, as defined by BMI greater than or equal to 30

- Self-reported binge eating as defined in DSM-5, in the last 4 weeks

- If sexually active with men, must agree to use birth control until the final study
visit is complete (e.g., barrier methods, oral contraceptive)

- Subject must be able to complete written informed consent procedures and be able to
comply with the requirements of the study.

Exclusion Criteria:

- Pregnant or breastfeeding

- Severe hypotension (< 90/60 mmHg)

- Recent or current use of vasoconstrictor or vasodilator medication

- Current or history of diabetes

- Allergies to any ingredients in naloxone hydrochloride

- History of or current alcoholism or drug dependence

- Bulimia Nervosa as defined in DSM 5

- Current or past use of opiate-containing medications in the last 30 days

- Plan to use opiate-containing medications during study participation period

- Medical conditions that are contraindicated with intranasal procedures: Nasal septal
abnormalities, nasal trauma, epistaxis, excessive nasal mucus, and intranasal damage
caused by the use of substances (e.g., cocaine)

- Presence of a condition or abnormality that in the opinion of the Investigator would
compromise the safety of the subject or the quality of the data